What does DR. STEFANIE CARDOEN, NEUROLOOG do?

DR. STEFANIE CARDOEN, NEUROLOOG is a specialist medical practice in Merelbeke-Melle. Private Limited, started on 12 October 2017, 1 establishment.

What is the address of DR. STEFANIE CARDOEN, NEUROLOOG?

The registered office of DR. STEFANIE CARDOEN, NEUROLOOG is located at Hoorndriesstraat 18A, 9820 Merelbeke-Melle.

Is DR. STEFANIE CARDOEN, NEUROLOOG still active?

Yes. According to the CBE (18 September 2026) DR. STEFANIE CARDOEN, NEUROLOOG is active, legal situation “Normale toestand”, started on 12 October 2017.

Is DR. STEFANIE CARDOEN, NEUROLOOG registered on Peppol?

Yes, DR. STEFANIE CARDOEN, NEUROLOOG is registered on the Peppol network with ID 0208:0682946118.

What is the enterprise number of DR. STEFANIE CARDOEN, NEUROLOOG?

The enterprise number of DR. STEFANIE CARDOEN, NEUROLOOG is BE0682946118.

When was DR. STEFANIE CARDOEN, NEUROLOOG founded?

DR. STEFANIE CARDOEN, NEUROLOOG was founded on 12 October 2017.

Who are the directors of DR. STEFANIE CARDOEN, NEUROLOOG?

According to the 2025 annual accounts, the directors of DR. STEFANIE CARDOEN, NEUROLOOG are: Stefanie Cardoen.

Is DR. STEFANIE CARDOEN, NEUROLOOG a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 12 October 2017; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did DR. STEFANIE CARDOEN, NEUROLOOG make in 2025?

DR. STEFANIE CARDOEN, NEUROLOOG posted a profit after taxes of € 137,789 in financial year 2025.

What is the revenue of DR. STEFANIE CARDOEN, NEUROLOOG?

As a small company, DR. STEFANIE CARDOEN, NEUROLOOG is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 187,287.

DR. STEFANIE CARDOEN, NEUROLOOG (Private Limited)

Dossier DR. STEFANIE CARDOEN, NEUROLOOG, printed on 18 September 2026 from databakkes.be/en/0682946118/dr-stefanie-cardoen-neuroloog. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

DR. STEFANIE CARDOEN, NEUROLOOG from Merelbeke-Melle, company number BE0682946118, closed financial year 2025 with a result of € 137,789 after tax. For that financial year DR. STEFANIE CARDOEN, NEUROLOOG recorded a gross margin of € 187,287 and equity of € 156,389. Compared with financial year 2024, the result moved from € 93,605 to € 137,789. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 29, 2026.

What it is worth Growing

€ 156,389

▲ 39% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 137,789

▲ 47% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 40,789

▲ € 33,021 vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 93,605 paid out

68 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Vehicles and equipment

€ 21,857

▼ 10% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Taxes

€ 1,852

▼ 3% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 77,804 Gross margin 2022: € 77,804 First fiscal year in the series	€ 136,719 Gross margin 2023: € 136,719 ▲ 76% vs 2022 (€ 77,804) Favourable step	€ 131,803 Gross margin 2024: € 131,803 ▼ 4% vs 2023 (€ 136,719) Unfavourable step	€ 187,287 Gross margin 2025: € 187,287 ▲ 42% vs 2024 (€ 131,803) Favourable step	▲ 42%
Profit after taxes	€ 50,928 Profit after taxes 2022: € 50,928 First fiscal year in the series	€ 100,408 Profit after taxes 2023: € 100,408 ▲ 97% vs 2022 (€ 50,928) Favourable step	€ 93,605 Profit after taxes 2024: € 93,605 ▼ 7% vs 2023 (€ 100,408) Unfavourable step	€ 137,789 Profit after taxes 2025: € 137,789 ▲ 47% vs 2024 (€ 93,605) Favourable step	▲ 47%
Equity	€ 71,388 Equity 2022: € 71,388 First fiscal year in the series	€ 120,868 Equity 2023: € 120,868 ▲ 69% vs 2022 (€ 71,388) Favourable step	€ 112,205 Equity 2024: € 112,205 ▼ 7% vs 2023 (€ 120,868) Unfavourable step	€ 156,389 Equity 2025: € 156,389 ▲ 39% vs 2024 (€ 112,205) Favourable step	▲ 39%
Total debts	€ 147,609 Total debts 2022: € 147,609 First fiscal year in the series	€ 77,249 Total debts 2023: € 77,249 ▼ 48% vs 2022 (€ 147,609) Favourable step	€ 89,391 Total debts 2024: € 89,391 ▲ 16% vs 2023 (€ 77,249) Unfavourable step	€ 36,760 Total debts 2025: € 36,760 ▼ 59% vs 2024 (€ 89,391) Favourable step	▼ 59%
Cash	€ 20,804 Cash 2022: € 20,804 First fiscal year in the series	€ 51,218 Cash 2023: € 51,218 ▲ 146% vs 2022 (€ 20,804) Favourable step	€ 7,768 Cash 2024: € 7,768 ▼ 85% vs 2023 (€ 51,218) Unfavourable step	€ 40,789 Cash 2025: € 40,789 ▲ € 33,021 vs 2024 (€ 7,768) Favourable step	▲ € 33,021
Retained profit	€ 52,788 Retained profit 2022: € 52,788 First fiscal year in the series	€ 102,268 Retained profit 2023: € 102,268 ▲ 94% vs 2022 (€ 52,788) Favourable step	€ 93,605 Retained profit 2024: € 93,605 ▼ 8% vs 2023 (€ 102,268) Unfavourable step	€ 137,789 Retained profit 2025: € 137,789 ▲ 47% vs 2024 (€ 93,605) Favourable step	▲ 47%
Dividend	€ 153,727 Dividend 2022: € 153,727 First fiscal year in the series	€ 50,928 Dividend 2023: € 50,928 ▼ 67% vs 2022 (€ 153,727) Unchanged	€ 102,268 Dividend 2024: € 102,268 ▲ 101% vs 2023 (€ 50,928) Unchanged	€ 93,605 Dividend 2025: € 93,605 ▼ 8% vs 2024 (€ 102,268) Unchanged	▼ 8%
Balance sheet total	€ 218,997 Balance sheet total 2022: € 218,997 First fiscal year in the series	€ 198,117 Balance sheet total 2023: € 198,117 ▼ 10% vs 2022 (€ 218,997) Unchanged	€ 201,595 Balance sheet total 2024: € 201,595 ▲ 2% vs 2023 (€ 198,117) Unchanged	€ 193,149 Balance sheet total 2025: € 193,149 ▼ 4% vs 2024 (€ 201,595) Unchanged	▼ 4%

Key figures of DR. STEFANIE CARDOEN, NEUROLOOG, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to DR. STEFANIE CARDOEN, NEUROLOOG?

What happened at DR. STEFANIE CARDOEN, NEUROLOOG in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 29, 2026 New annual accounts for financial year 2025: profit of € 137,789 (▲ 47% vs 2024). Source: NBB ↗
Oct 12, 2017 New establishment in Merelbeke-Melle. KBO
2017 Stefanie Cardoen became a director. NBB
Oct 12, 2017 Start of the company according to the CBE. KBO

In short

From € 50,928 profit in 2022 to € 137,789 profit in 2025.

Paid € 114,358 in corporate taxes since 2022.

Best year ever: 2025, with € 137,789 profit.

Paid out € 400,527 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at DR. STEFANIE CARDOEN, NEUROLOOG? We notify you, reason included.

Follow DR. STEFANIE CARDOEN, NEUROLOOG

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Stefanie Cardoen

DR. STEFANIE CARDOEN, NEUROLOOG

Behind DR. STEFANIE CARDOEN, NEUROLOOG is Stefanie Cardoen.

See the full network in the app

Directors

According to the 2025 annual accounts

Stefanie Cardoen

Director

since 2017

Establishments

Establishment units

Physical locations of this company

Registered office

Hoorndriesstraat 18A

9820 Merelbeke-Melle

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0682.946.118
VAT number: BE 0682.946.118
Registered office: Hoorndriesstraat 18A, 9820 Merelbeke-Melle
Names & denominations: DR. STEFANIE CARDOEN, NEUROLOOG
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 12 October 2017
Peppol: Active · Active since 2 Jun 2025
Activities · NACE: Activiteiten van medisch specialisten

View on CBE Public ↗ Annual accounts (NBB) ↗